MedTrace Logo

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

NCT00369603 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2013-04-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether standard medications approved for Alzheimer's disease treatment differ in their action on brain functioning and whether any observed brain activity differences as result of treatment are associated with particular patterns of dementia improvement or reduced decline.

Conditions

Interventions

DRUG

Razadyne ER

4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER

DRUG

Aricept

8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept

Sponsors & Collaborators

  • Ortho-McNeil Neurologics, Inc.

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Jeffrey N Browndyke, PhD · Duke University

  • Roberto Cabeza, PhD · Duke University

  • James R Burke, PhD · Duke University

  • Kathleen Welsh-Bohmer, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-10-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00369603 on ClinicalTrials.gov